<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Cao, Kim I.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Concomitant TMZ Does Not Improve Effectiveness of WBRT for Brain Metastases from Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">Temozolomide, an oral alkylating agent, has radiosensitizing properties and has demonstrated promise in previous phase 2 studies involving whole-brain radiation therapy. However, these studies did not include sufficient samples of patients with brain metastases from breast cancer, despite the need for improved treatments for such patients. This article discusses data from a phase 2 prospective randomized multicenter study looking at if the addition of TMZ improves the efficacy of WBRT.</style></abstract><number><style face="normal" font="default" size="100%">31</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>